Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients

被引：0
作者：
Lívia Rojkó
Lilla Reiniger
Vanda Téglási
Katalin Fábián
Orsolya Pipek
Attila Vágvölgyi
László Agócs
János Fillinger
Zita Kajdácsi
József Tímár
Balázs Döme
Zoltán Szállási
Judit Moldvay
机构：
[1] National Korányi Institute of Pulmonology,VI. Department of Pulmonology
[2] Semmelweis University,1st Department of Pathology and Experimental Cancer Research
[3] Semmelweis University,MTA
[4] Semmelweis University,SE NAP, Brain Metastasis Research Group, 2nd Department of Pathology, Hungarian Academy of Sciences
[5] Szent Imre Teaching Hospital,Department of Pulmonology
[6] Eötvös Loránd University,Department of Pathology
[7] National Korányi Institute of Pulmonology,Department of Physics of Complex Systems
[8] National Institute of Oncology-Semmelweis University,Department of Thoracic Surgery
[9] National Korányi Institute of Pulmonology,Department of Thoracic Surgery
[10] National Institute of Oncology,Department of Pathology
[11] Semmelweis University,Department of Pathology
[12] National Korányi Institute of Pulmonology-Semmelweis University,2nd Department of Pathology
[13] Medical University of Vienna,Department of Tumor Biology
[14] Harvard Medical School,Comprehensive Cancer Center, Division of Thoracic Surgery
[15] Technical University of Denmark,Children’s Hospital Informatics Program at the Harvard–Massachusetts Institute of Technology, Division of Health Sciences and Technology
来源：
Journal of Cancer Research and Clinical Oncology | 2018年 / 144卷
关键词：
PD-L1; PD-1; Immunohistochemistry; Lung cancer; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1219 / 1226
页数：7
相关论文
共 206 条
[11]  
Doi T(2015)Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) J Clin Oncol 33 8010-undefined
[12]  
Ishikawa T(2017)Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis Neuro Oncol 6 244285-undefined
[13]  
Okayama T(2011)International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 57 91-undefined
[14]  
Oka K(1990)Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma Eur J Cancer (Oxford England) 45 1470-undefined
[15]  
Mizushima K(2008)Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis Mol Immunol 107 1563-undefined
[16]  
Yasuda T(2016)Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy Cancer Sci undefined undefined-undefined
[17]  
Sakamoto N(undefined)undefined undefined undefined undefined-undefined
[18]  
Katada K(undefined)undefined undefined undefined undefined-undefined
[19]  
Kamada K(undefined)undefined undefined undefined undefined-undefined
[20]  
Uchiyama K(undefined)undefined undefined undefined undefined-undefined
12345678910